HuiTai Biomedicine is a leading biotech company committed to the R&D of novel therapeutics for the treatment of Fibrotic Diseases through creating TGF-β therapeutics based on the precise and targeted regulation of TGF-β signaling. HuiTai is developing innovative therapeutics to address the most severe and difficult-to-treat fibrotic conditions of the lung, liver, kidney and other organs. We have created several prospective breakthrough treatments for Fibrotic Diseases, such as Idiopathic Pulmonary Fibrosis (IPF), Hepatic Fibrosis, Renal Fibrosis and more deadly fibrosis indications with enormous unmet clinical needs. HuiTai Biomedicine is located in Chengdu City, Sichuan Province, the Southwest of China. The company is established with the goal that Fibrotic Diseases will no longer bother anyone and everyone, financed by its founders and executives whose loved family members die of Fibrotic Diseases. That is the reason why we are persistently developing prominent treatments for the patients and their families. Our first product:HTPEP-001, is a global first-in-class therapeutic suppressing active TGF-β1 production and Smad signaling by targeting TSP-1. HTPEP-001 is designed to block the progression of fibrosis in vivo without systemic side effects of TGF-β inhibition or side effects of blocking physiological fibrosis. For more information, please visit: (1)American Thoracic Society (ATS) 2018 Annual Meeting; https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2018.197.1_MeetingAbstracts.A1631 (2)American Thoracic Society (ATS) 2020 Annual Meeting; https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A2286 (3)American Society of Clinical Oncology (ASCO) 2020 annual meeting; https://meetinglibrary.asco.org/record/189707/abstract